Billiontoone (NASDAQ:BLLN) Price Target Cut to $90.00 by Analysts at Wells Fargo & Company

Billiontoone (NASDAQ:BLLN) had its price target cut by Wells Fargo & Company from $110.00 to $90.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also recently issued reports about the company. Guggenheim restated a “buy” rating and set a $120.00 price objective on shares of Billiontoone in a research note on Thursday. William Blair initiated coverage on shares of Billiontoone in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Zacks Research raised shares of Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. BTIG Research dropped their price objective on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.57.

Billiontoone Stock Down 10.7%

NASDAQ:BLLN opened at $72.17 on Thursday. The firm has a market capitalization of $3.30 billion and a P/E ratio of 721.70. Billiontoone has a one year low of $66.00 and a one year high of $138.70. The stock has a 50-day moving average price of $85.87.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $96.05 million for the quarter, compared to the consensus estimate of $85.85 million. The firm’s revenue was up 113.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Green Alpha Advisors LLC acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $436,000. FNY Investment Advisers LLC acquired a new stake in Billiontoone in the 4th quarter valued at approximately $497,000. Massachusetts Financial Services Co. MA acquired a new stake in Billiontoone in the 4th quarter valued at approximately $13,373,000. Baillie Gifford & Co. bought a new stake in Billiontoone during the 4th quarter valued at $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Billiontoone during the 4th quarter worth $1,348,000.

Key Stories Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat and company raised 2026 revenue guidance — BillionToOne reported $0.11 EPS (vs. $0.04 consensus) and $96.05M revenue (vs. $85.85M est.), with revenue up 113% year/year; management raised FY‑2026 revenue guidance to $430M–$445M (well above street consensus). This is the core bullish fundamental catalyst. GlobeNewswire: Earnings & Guidance
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating with a $120 price target — a supportive analyst vote that implies meaningful upside from current levels. Benzinga: Guggenheim Rating
• Neutral Sentiment: BTIG cut its price target from $160 to $140 but kept a “buy” rating — still constructive long-term, though the lower PT trims upside expectations. StreetInsider: BTIG PT Lowered
• Neutral Sentiment: Reported short interest entries show zero/NaN values and a 0.0 days ratio — the data appears unreliable and is unlikely to explain today’s move. (No meaningful short-interest signal.)
• Negative Sentiment: Wells Fargo lowered its price target from $110 to $90 and set an “equal weight” rating — a clear downdraft to near‑term sentiment and one of the more immediate bearish analyst actions. Benzinga: Wells Fargo PT Cut

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.